以左侧胸腔积液为表现的肺神经内分泌肿瘤
Pulmonary Neuroendocrine Tumor Presenting as a Left Pleural Effusion.
作者信息
Ortiz Miguel A, Montes Gabriela, Cantres Onix, Rodríguez William
机构信息
is a Pulmonary and Critical Care Physician, is a Physician, is a Pulmonologist, and is Chief, Pulmonary and Critical Care Medicine and Training Program Director, all at VA Caribbean Health Care System in San Juan, Puerto Rico.
出版信息
Fed Pract. 2020 Jun;37(6):290-294.
Abstract
The presence of a symptomatic and recurrent unilateral pleural effusion should alert physicians to consider thoracentesis with mindful use of biomarkers not only for therapeutic purposes, but also for diagnosis of both benign and malignant etiologies.
摘要
有症状的复发性单侧胸腔积液的出现应提醒医生考虑进行胸腔穿刺术，并谨慎使用生物标志物，这不仅是为了治疗目的，也是为了诊断良性和恶性病因。
相似文献
1
Pulmonary Neuroendocrine Tumor Presenting as a Left Pleural Effusion.以左侧胸腔积液为表现的肺神经内分泌肿瘤
Fed Pract. 2020 Jun;37(6):290-294.
2
Mortality among patients with pleural effusion undergoing thoracentesis.接受胸腔穿刺术的胸腔积液患者的死亡率。
Eur Respir J. 2015 Aug;46(2):495-502. doi: 10.1183/09031936.00217114. Epub 2015 Apr 2.
3
Endoscopic ultrasound-guided transesophageal thoracentesis for minimal pleural effusion.内镜超声引导下经食管胸腔穿刺术治疗微量胸腔积液
Indian J Gastroenterol. 2018 May;37(3):231-234. doi: 10.1007/s12664-018-0861-x. Epub 2018 Jun 19.
4
Sensitivity of Initial Thoracentesis for Malignant Pleural Effusion Stratified by Tumor Type in Patients with Strong Evidence of Metastatic Disease.在有明确转移证据的患者中，根据肿瘤类型分层的初次胸腔穿刺术对恶性胸腔积液的敏感性。
Respiration. 2018;96(4):363-369. doi: 10.1159/000490732. Epub 2018 Jul 17.
5
A randomized, phase III, double-blind, placebo-controlled trial of intrapleural instillation of methylprednisolone acetate in the management of malignant pleural effusion.一项关于醋酸甲泼尼龙胸膜腔内注射治疗恶性胸腔积液的随机、III期、双盲、安慰剂对照试验。
Chest. 2003 Mar;123(3):822-7. doi: 10.1378/chest.123.3.822.
6
[Contribution of pleural fluid analysis to the diagnosis of pleural effusion].[胸腔积液分析对胸腔积液诊断的贡献]
Med Clin (Barc). 2015 Aug 21;145(4):171-7. doi: 10.1016/j.medcli.2014.08.005. Epub 2014 Nov 27.
7
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.通过结合临床、放射学和胸水分析参数预测恶性及准恶性胸腔积液
Lung. 2017 Oct;195(5):653-660. doi: 10.1007/s00408-017-0032-3. Epub 2017 Jun 27.
8
Malignant Pleural Effusion: Still a Long Way to Go.恶性胸腔积液：仍有很长的路要走。
Rev Recent Clin Trials. 2019;14(1):24-30. doi: 10.2174/1574887114666181204105208.
9
[Thoracentesis and pleurodesis in the treatment of pleural effusion. Personal experience].[胸腔穿刺术及胸膜固定术治疗胸腔积液。个人经验]
G Chir. 2008 Jun-Jul;29(6-7):299-304.
10
Patterns of pleural pressure amplitude and respiratory rate changes during therapeutic thoracentesis.治疗性胸腔穿刺过程中胸膜压力幅度和呼吸频率变化的模式。
BMC Pulm Med. 2018 Feb 14;18(1):36. doi: 10.1186/s12890-018-0595-7.
引用本文的文献
1
Pleural carcinoid diagnosed via video-assisted thoracoscopy biopsies in a patient with recurrent unilateral pleural effusion at St. Francis hospital Nsambya: a case report.在恩桑比亚圣弗朗西斯医院，通过电视辅助胸腔镜活检诊断出的一例患有复发性单侧胸腔积液患者的胸膜类癌：病例报告
J Med Case Rep. 2024 Dec 19;18(1):625. doi: 10.1186/s13256-024-04891-8.
本文引用的文献
1
Biomarkers in the diagnosis of pleural diseases: a 2018 update.胸腔疾病诊断中的生物标志物：2018 年更新。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808660. doi: 10.1177/1753466618808660.
2
Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer.较高的预处理乳酸脱氢酶浓度预示着肺癌患者的总生存期更差。
Medicine (Baltimore). 2018 Sep;97(38):e12524. doi: 10.1097/MD.0000000000012524.
3
Molecular alterations of neuroendocrine tumours of the lung.肺神经内分泌肿瘤的分子改变。
Histopathology. 2018 Jan;72(1):142-152. doi: 10.1111/his.13394.
4
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.现行世卫组织指南与免疫组织化学标志物在非小细胞肺癌（NSCLC）分类中的关键作用：从靶向治疗到免疫治疗。
Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109. doi: 10.1016/j.semcancer.2017.11.019. Epub 2017 Nov 26.
5
Classification of pulmonary neuroendocrine tumors: new insights.肺神经内分泌肿瘤的分类：新见解
Transl Lung Cancer Res. 2017 Oct;6(5):513-529. doi: 10.21037/tlcr.2017.09.04.
6
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.唯有 NET：神经内分泌肿瘤和癌综述。
Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5.
7
Recent updates on grading and classification of neuroendocrine tumors.神经内分泌肿瘤分级与分类的最新进展
Ann Diagn Pathol. 2017 Aug;29:11-16. doi: 10.1016/j.anndiagpath.2017.04.005. Epub 2017 Apr 13.
8
Low Grade Neuroendocrine Tumors of the Lung.肺低级别神经内分泌肿瘤
Front Oncol. 2017 Jun 13;7:119. doi: 10.3389/fonc.2017.00119. eCollection 2017.
9
Pleural fluid cytology samples in cases of suspected lung cancer: An experience from a tertiary care centre.疑似肺癌病例的胸腔积液细胞学样本：来自三级医疗中心的经验
Diagn Cytopathol. 2017 Mar;45(3):195-201. doi: 10.1002/dc.23659. Epub 2017 Jan 23.
10
Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.肺神经内分泌肿瘤：分化良好疾病的诊断和治疗的当前挑战和进展。
J Thorac Oncol. 2017 Mar;12(3):425-436. doi: 10.1016/j.jtho.2016.11.2222. Epub 2016 Nov 24.
Zotero 插件